Emcure Pharma registers 18% revenue growth, 30% PAT in Q3 of FY 25

New Delhi: Emcure Pharmaceuticals has announced its unaudited consolidated financial results for the quarter ended December 31^st, 2024.

The quarter saw strong growth led by the International businesses that grew 23% YoY. The Canadian business continues to perform well, achieving a 34% YoY growth and the Mantra subsidiary is now fully integrated. Company’s Rest of the World (RoW) market business grew a robust 40% YoY aided by strong growth in our non-ARV segment.

The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12% to ₹ 888 Cr, led by a steady performance in the base business and aided by in-licensed products.

Revenue from company’s operations stood at Rs 1,963 Cr, up 17.7% YoY and PAT at 156Cr, up 30.3% YoY. EBITDA margins at 18.4% with EBITDA up 23.2% YoY.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”